Additionally, the 36-month beta value for ARQT is 1.78. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 3 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for ARQT is 104.79M and currently, short sellers hold a 16.01% ratio of that float. The average trading volume of ARQT on June 25, 2025 was 2.19M shares.
ARQT) stock’s latest price update
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) has seen a rise in its stock price by 2120455 in relation to its previous close of 14.4. However, the company has experienced a 6.94% gain in its stock price over the last five trading sessions. seekingalpha.com reported 2025-06-12 that Arcutis Biotherapeutics stands out in biotech for its impressive factor grades, which are rare in this sector. The recent FDA approval of ZORYVE Topical foam opens a significant revenue and profitability opportunity for Arcutis. FDA approval removes a major risk, allowing the company to commercialize and market its drug after years of costly R&D.
ARQT’s Market Performance
Arcutis Biotherapeutics Inc (ARQT) has seen a 6.94% rise in stock performance for the week, with a 4.90% gain in the past month and a -17.12% plunge in the past quarter. The volatility ratio for the week is 2.05%, and the volatility levels for the past 30 days are at 2.66% for ARQT. The simple moving average for the last 20 days is 4.61% for ARQT stock, with a simple moving average of 12.79% for the last 200 days.
Analysts’ Opinion of ARQT
Many brokerage firms have already submitted their reports for ARQT stocks, with H.C. Wainwright repeating the rating for ARQT by listing it as a “Buy.” The predicted price for ARQT in the upcoming period, according to H.C. Wainwright is $19 based on the research report published on December 30, 2024 of the previous year 2024.
Jefferies, on the other hand, stated in their research note that they expect to see ARQT reach a price target of $15. The rating they have provided for ARQT stocks is “Buy” according to the report published on August 28th, 2024.
Mizuho gave a rating of “Buy” to ARQT, setting the target price at $8 in the report published on January 03rd of the previous year.
ARQT Trading at 3.17% from the 50-Day Moving Average
After a stumble in the market that brought ARQT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -19.27% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ARQT starting from Welgus Howard G., who sale 10,139 shares at the price of $13.37 back on Jun 18 ’25. After this action, Welgus Howard G. now owns 109,414 shares of Arcutis Biotherapeutics Inc, valued at $135,574 using the latest closing price.
Stock Fundamentals for ARQT
Current profitability levels for the company are sitting at:
- -0.57 for the present operating margin
- 0.88 for the gross margin
The net margin for Arcutis Biotherapeutics Inc stands at -0.61. The total capital return value is set at -0.48. Equity return is now at value -70.58, with -31.54 for asset returns.
Based on Arcutis Biotherapeutics Inc (ARQT), the company’s capital structure generated 0.44 points at debt to capital in total, while cash flow to debt ratio is standing at -1.0. The debt to equity ratio resting at 0.78. The interest coverage ratio of the stock is -7.26.
Currently, EBITDA for the company is -109.62 million with net debt to EBITDA at -0.54. When we switch over and look at the enterprise to sales, we see a ratio of 8.3. The receivables turnover for the company is 2.49for trailing twelve months and the total asset turnover is 0.62. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.55.
Conclusion
In conclusion, Arcutis Biotherapeutics Inc (ARQT) has seen better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
